Cencora, a global healthcare company, has unveiled its new initiative, Accelerate Pharmacy Solutions, aimed at enhancing support for hospital and health system customers. This unified portfolio of services is designed…
BrightPath Bio (Tokyo Stock Exchange Growth 4594), a leader in iPS cell-derived Natural Killer T (NKT) cell therapy, and Cellistic, a pioneer in advanced iPS cell therapy manufacturing, have announced…
Galderma has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of nemolizumab for the treatment…
Nintx (Next Innovative Therapeutics), a Brazilian biotech company focused on developing treatments for multifactorial diseases using Brazil’s rich biodiversity, has raised an additional US$ 10 million following a US$ 3…
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial. The trial evaluated the combination of lunresertib…
SamanTree Medical, a leader in oncologic surgical imaging innovation, announced promising results from the SHIELD study, to be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) on Dec.…
The Menarini Group, a global leader in pharmaceuticals and diagnostics, and its subsidiary Stemline Therapeutics, focused on delivering innovative oncology treatments, have partnered with MEDSIR, a top independent clinical research…
Researchers from City of Hope®, a leading cancer research and treatment organization in the United States, presented new findings at the 2024 ASH conference in San Diego, California, from December…
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR® AI platform, announced today the enrollment and dosing of the first patient in Taiwan…
DNAnexus, Inc., a leader in precision health data platforms, and Panomics, Inc., specializing in AI-powered omics data management and discovery for biopharma, have announced a strategic collaboration. This partnership will…
MaaT Pharma will host a KOL webinar on December 17th, 2024, to discuss the data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) – Register here. Key Results:…
ReAlta Life Sciences, Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, announced promising preclinical data for its lead asset,…